Radiogenomic evaluation of tumour response to targeted agents
Radiogenomics should be an integral part of drug development, according to Dr Korn who talks to ecancer about this evolving field at TAT 2015.
Imaging Endpoints News
Radiogenomics should be an integral part of drug development, according to Dr Korn who talks to ecancer about this evolving field at TAT 2015.
Featured Webinar:
Radiologic Analysis of COVID-19 Infection
June 23, 2020
